SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp is trending amid intense investor debate surrounding its recent earnings report, which highlighted strong revenue growth but raised concerns about rising operating expenses. The community is actively locked in a standoff between bulls anticipating long-term gains from AI-driven platform expansions and PDT rule updates, and bears citing potential manipulation and ongoing profitability struggles.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. is rallying following news that it signed a letter of intent for federal funding and equity participation as part of a multi-billion dollar U.S. government investment package into the quantum computing sector. While the community is debating the stock's fundamental valuation and the dilutive nature of the government's equity stake, investors are heavily focused on the potential for a significant short squeeze and long-term sector validation.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending following the U.S. government's announcement of a significant $1 billion CHIPS Act award to help the company launch a dedicated quantum chip foundry. The community is actively discussing the stock's potential as a 'godfather' of quantum computing, with many traders debating whether this government-backed catalyst will drive a sustained rally toward the $300 level.

Applied Digital Corporation

Applied Digital is surging following the announcement of a massive new hyperscaler lease that pushes the companys total contracted capacity past a major milestone. The community is buzzing with optimism, fueled by multiple analyst price target upgrades and active discussions around the potential for a significant short squeeze as the stock attracts increased institutional and retail interest.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is surging following a landmark letter of intent with the U.S. Department of Commerce, which grants the firm up to $100 million in federal funding as part of a broader government push to secure domestic quantum leadership. The community is buzzing over this validation, with many investors actively debating the shifting competitive landscape among pure-play quantum firms and the potential for a significant re-rating of the sector.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is currently trending as community members closely monitor its Bitcoin treasury growth and the integration of its daily dividend program. Investors are actively discussing the stock's potential as a play on Bitcoin's long-term performance while debating the impact of institutional activity and treasury management strategies.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending due to significant trading volume and positive sentiment following a fireside chat where management highlighted QNX's critical role in the expanding physical AI and robotics markets. The community is heavily focused on the company's long-term potential as a foundational software provider, with many investors pointing to key government re-certifications and management's confident outlook on growth as catalysts for future valuation gains.

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.

Akari Therapeutics Plc - ADR

Akari Therapeutics

Akari Therapeutics is trending as investors react to promising preclinical data for its oncology platform and strategic management changes, fueling speculation around potential partnerships and future growth. The community remains focused on the company's efforts to regain compliance, the impact of its recent financing, and the high-conviction participation of insiders in the firm's equity.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending as investors react to a double beat in quarterly results and raised margin guidance, with the community actively debating whether the company's AI-driven growth can overcome ongoing fears regarding software-as-a-service market durability. While some participants express optimism over the company's robust AI adoption and execution, others remain cautious, highlighting the high volatility of recent earnings reactions across the software sector.

GLOBALFOUNDRIES, Inc. provides foundry services and manufactures semiconductors. It offers global shuttle, mask, post-fab and turnkey services. The company was founded on October 7, 2008 and is headquartered in Malta, NY.

GlobalFoundries Inc

GlobalFoundries is trending as it secures a significant equity grant from the U.S. government to scale quantum computing and advanced chip manufacturing, fueling community optimism about its role in domestic semiconductor sovereignty. Traders and investors are actively discussing the stock's recent breakout to 52-week highs, debating whether this government backing represents a long-term growth catalyst for its non-pure-play business model.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 14.7%

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 2,269,065 shares, a drop of 14.7% from the March 31st total of 2,660,931 shares. Approximately 4.0% of the company's stock are...

Pyxis Oncology (NASDAQ:PYXS) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen upgraded shares of Pyxis Oncology from a "sell" rating to a "hold" rating in a research report on Monday...

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold ratin...

Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell

Wall Street Zen lowered Pyxis Oncology from a "hold" rating to a "sell" rating in a report on Sunday...

Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Pyxis Oncology from a "sell" rating to a "hold" rating in a research note on Saturday...

Rachel Humphrey Sells 13,896 Shares of Pyxis Oncology (NASDAQ:PYXS) Stock

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) Director Rachel Humphrey sold 13,896 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of...

Q1 EPS Estimates for Pyxis Oncology Raised by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Pyxis Oncology in a report issued on Tuesday, March...

Pyxis Oncology (NASDAQ:PYXS) Director Rachel Humphrey Sells 13,896 Shares

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) Director Rachel Humphrey sold 13,896 shares of the business's stock in a transaction dated Monday, April 21st. The shares were sold at an average...

FY2029 EPS Estimates for Pyxis Oncology Lifted by Analyst

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at HC Wainwright upped their FY2029 earnings per share estimates for shares of Pyxis Oncology in a research report issued on Tuesday, March...

Stifel Nicolaus Lowers Pyxis Oncology (NASDAQ:PYXS) Price Target to $8.00

Stifel Nicolaus decreased their price target on shares of Pyxis Oncology from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Current Price	$1.94
Prev Close	$2.00
Open	$2.01
Dividend Yield	0.00%
50-Day Moving Average	$1.77
Beta	1.51
Avg. Volume	383,806.23
PE Ratio	-1.49

52-Week High	$5.55
52-Week Low	$0.97
Market Capitalization	$126.71M
EPS (Annual)	-$1.28
Price to Book	3.90
Revenue Per Employee	$247,464.29

PYXS
Pyxis Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest PYXS News

PYXSPyxis Oncology Inc